Retrospective review of neonates with persistent pulmonary hypertension of the newborn at Charlotte Maxeke Johannesburg academic hospital (CMJAH) by Harerimana, I
  
UNIVERSITY OF THE WITWATERSRAN 
SCHOOL OF CLINICAL MEDICINE 
DEPARTMENT OF PAEDIATRICS AND CHILD HEALTH 
 
RESEARCH REPORT 
TITLE: Retrospective review of neonates with Persistent Pulmonary Hypertension of the          
                Newborn at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH)  
.  
CANDIDATE: Dr I. HARERIMANA 
STUDENT No:  500229                         
 
SUPERVISOR:  Prof. D.E BALLOT 
                                
                                
Research report submitted in partial fulfilment of requirements for a Master of Medicine 
degree in Paediatrics and Child Health (MMed). 
 
 
 
November 2014
i 
 
DECLARATION 
I, Innocent HARERIMANA, declare that this research report is my own original work. It is 
being submitted for the degree of Master of Medicine in Paediatrics and Child Health at the 
University of the Witwatersrand, Johannesburg. It has not been submitted before for any 
degree or examination at this or any other University. 
 
Signed…........................................... 
The.............day of ..................2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii 
 
DEDICATION 
To my wife Jeanne d’Arc and my son Maxime who bring so much joy to my life. Your love 
and support are invaluable.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGEMENTS 
This work would not have been successful without the guidance, help and support of number 
of individuals. I would like to express my profound thanks to them. 
I would like to express my sincere gratitude to Professor Daynia Ballot who suggested the 
research topic to me and accepted to supervise this research. Her commitment, guidance and 
support have been invaluable.  
I would like to thank Professor Peter Cooper and other members of Wits Paediatric 
Department for accepting and giving me a chance to train in this department.  
I would like also to express my deepest gratitude to the Rwandan government for sponsoring 
my training. 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
ABSTRACT  
 
Background: Persistent pulmonary hypertension of the newborn (PPHN) is a clinical 
syndrome characterised by high pulmonary pressure, low systemic pressures and severe 
hypoxemia due to failure of circulation transition after birth. 
Objective: The aim of the study was to determine the incidence, describe the risk factors, 
patient’s characteristics, and treatment strategies for PPHN at CMJAH over the last 8 years 
and discuss the possible need of ECMO treatment in our settings. 
Patients and methods: This was a retrospective descriptive study. I reviewed the computer 
database and medical records of infants who had a discharge diagnosis of PPHN from 
January 2006 to December 2013. The study included term and preterm, inborn and outborn 
infants. PPHN diagnosis was mainly based clinical suspicion. Patients with congenital 
cyanotic heart defect were excluded.  
Results:  The incidence of PPHN was estimated at 0.33 per 1000 live births in our unit. Out 
of 81 infants who had a discharge diagnosis of PPHN 72 patients were included in the study. 
Of the 72 patients 37(51.4%) were female, 38 (52.8%) born by vaginal delivery and 
44(61.1%) were inborn. Most of them (75%) were born at term and had an appropriate 
weight for gestation age. The mean birth weight was 2.94 kg (SD 0.69) while mean gestation 
age was 38.2 weeks (SD3.3). Meconium aspiration syndrome (MAS) seen in 43 patients 
(59.7%) was the most frequent underlying disease followed by pneumonia that was seen in 9 
patients (12.5 %). Of the 72 patients 67(93.1%) were treated with mechanical ventilation and 
only18.1% of them required high frequency oscillatory ventilation. Magnesium sulfate and 
Sildenafil were used in 12 patients (16.7%) and 9 patients (12.5%) respectively, while inhaled 
nitric oxide and extracorporeal membrane oxygenation were not available. Of the 72 patients 
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25(34.7%) died. The patients’ characteristics were similar between survivors and non-
survivors. The need for inotropic support was associated with a poor outcome. 
Conclusion: PPHN was uncommon in our unit, but its management is still a challenge since 
it was associated with a high mortality. The leading cause of PPHN was MAS which can 
possibly be prevented by improving both antenatal and intrapartum obstetric care by good 
management of at-risk pregnancies. In our settings, the reduction of MAS incidence, 
adequate neonatal resuscitation, surfactant replacement therapy and early initiation of assisted 
ventilation for depressed infants with MAS could be cost- effective measures in preventing 
PPHN. ECMO therapy is very expensive and labour intensive, thus its use is limited in low- 
and middle- income countries including South Africa.  
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1. INTRODUCTION 
1.0. Background 
 
Persistent pulmonary hypertension of the newborn (PPHN) is a clinical condition 
characterised by severe respiratory failure and hypoxemia (1). Its incidence is estimated 
about 2 per 1000 live births across the world and it is associated with a high morbidity and 
mortality (2, 3). Despite the progress made in treatment of PPHN, it is still, not infrequently, 
a fatal disease especially in resource – limited settings (4). Walsh-Sukys et al. (2) reported an 
overall mortality  of 11% (range 4%-33%) in a multicentre study in USA, Razzaq et al. (5) 
reported a mortality of  26.6%  at Multan Children’s Hospital in Parkistan and Abdel et al. (6) 
reported a mortality of 25%  at Al-Minya University Hospital in Egypt.  
In South Africa, previous studies reported the incidence of PPHN to be 1.1%, with a 
mortality rate  of  31% at Tygerberg Children’s Hospital as reported by Smith et al. (7)  and 
48% at Chris Hani Baragwanath Hospital as reported by Velaphi et al. (8). PPHN is due to 
failure of circulatory transition at birth, when pulmonary artery pressure (PAP) remains 
higher than  systemic pressures (9) and the consequent right- to- left shunting of  blood 
through patent foramen ovale (PFO) and/ or  patent ductus arteriosus (PDA) results in severe 
hypoxemia (1, 10, 11) . PPHN  usually affects term or near- term  newborn  babies though 
preterm babies can also be affected (1).  This clinical condition  was initially called persistent 
foetal circulation (PFC), but it was later named persistent pulmonary hypertension of the 
newborn to better describe its pathophysiology (11). PPHN is most commonly secondary to 
an underlying pulmonary pathology although primary or idiopathic PPHN is also frequent (1, 
10, 11). Meconium Aspiration Syndrome (MAS) was the leading cause of PPHN (42%), 
followed by idiopathic PPHN (27%), respiratory distress syndrome (RDS) (17%), 
pneumonia/sepsis (13%) and less frequently lung hypoplasia as reported by Konduri et al. 
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(11) in a multicentre trial of inhaled nitric oxide (iNO ). The other perinatal conditions that 
are potential risk factor of PPHN include perinatal asphyxia, polycythemia, acidosis and 
hypothermia (3).   
PPHN is suspected when there is a significant difference between pre-ductal and post-ductal 
oxygen saturation, in combination with severe hypoxemia that does not improve when the 
infant is put on 100% supplemental oxygen. However it is difficult to accurately differentiate 
PPHN from cyanotic congenital heart disease only by clinical examination, so 
echocardiography is usually required to confirm a diagnosis of PPHN (1, 3).  
Remarkable progress has been made in the management of this condition even though it 
frequently remains fatal in poorly-resourced facilities (4). The survival of infants suffering 
from PPHN has been improved by new medical technologies such as high frequency 
oscillatory ventilation (HFOV), selective pulmonary vasodilators such as iNO and 
phosphodiesterase inhibitors (Sildenafil and milrinone), surfactant and extracorporeal 
membrane oxygenation (ECMO) (3, 10-15). In resource-limited facilities, sildenafil and 
magnesium sulphate have been shown to be safe and effective pulmonary vasodilators and to 
improve oxygenation when iNO is not available (16-19).  Adjuvant treatments such as 
inotropic support, correction of metabolic disturbances and minimal handling also play an 
invaluable role in the treatment of these infants (11, 15). Alkalinisation either by alkali 
infusion or hyperventilation has been abandoned because of consequent neurological 
complications and increased risk of developing chronic lung disease (11, 15).  The current 
mainstay of PPHN treatment consists of a combination of HFOV and iNO. This combination 
treatment has been shown to reduce the need for ECMO rather than using each one of them 
separately (10, 13). However it does not reduce the mortality or duration of hospitalisation 
(13), and there is still unresolved debate and controversies among neonatologists regarding 
the appropriate time and  dosage of initiation of the iNO treatment in newborn (10). 
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ECMO is used as a rescue therapy for infants in respiratory failure, unresponsive to other 
therapies (20, 21). Though it is very expensive and labour intensive, its introduction has 
remarkably changed the outcome of infants suffering from PPHN in well- equipped centres 
(22, 23). ECMO is generally not offered at CMJAH due to resource constraints; however, the 
cardiothoracic unit does offer ECMO to certain neonates. Locally it is worth considering 
whether we have the capacity to offer this therapy – would it be appropriate or required? 
PPHN is a fatal clinical syndrome and MAS, the leading cause of PPHN, is more frequent in 
our settings. However there is paucity of data in literature regarding the management of 
PPHN in resource-limited settings. Therefore we undertook a retrospective review of the 
CMJAH computer database to determine the incidence, describe the risk factors, the patients’ 
characteristics and treatment modalities for PPHN at CMJAH over the last 8 years and 
discuss the possible need of ECMO treatment in our settings. 
1.1. Literature review  
 
The literature review was based on the premise that persistent pulmonary hypertension of the 
newborn is a clinical syndrome resulting from failure or maladaptation of foetal pulmonary 
circulation at birth (4, 24). 
1.1.1 Foetal circulation  
 
The foetal circulation is characterised by high pulmonary vascular resistance (PVR) and low 
systemic vascular resistance (SVR). Elevated PVR is due to factors like low oxygen tension, 
elevated levels of vasoconstrictor mediators such as endothelin-1(ET-1) and Thromboxane A2 
(TXA2), and low levels of vasodilators such as nitric oxide and prostacyclin (PGI2) during 
foetal life. The foetal lungs are fluid filled and do not participate in gas exchange: they only 
receive 5-10% of the right ventricle output, and the gas exchange function is performed by 
the placenta (1, 10, 25). Recent studies have shown that pulmonary blood flow varies with 
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gestation age : it increases from 13% to 25% of the cardiac output  at 20 and 30 weeks of 
gestation  respectively and decreases to 21%  at  38 weeks of gestation (26).  
1.1.2.   Adaptation of pulmonary circulation at birth  
 
At birth, clamping of the umbilical cord and removal of the placenta  increases the SVR in 
infants and the PVR abruptly falls due to the increase in oxygen tension, levels of 
vasodilators such as NO and PGI2, decrease of vasoconstrictors such as ET-1 and TXA2 and 
lung expansion. Pulmonary vasodilatation results in increased pulmonary blood flow and the 
lungs take over gas exchange function; the increased systemic pressures induce closure of the 
foramen ovale and improved oxygenation (13). The main determinants of perinatal 
circulation transition are NO- cyclic guanosine monophosphate (cGMP) pathway (regulated 
by endothelial nitric oxide synthase and soluble guanylyl cyclase), and arachidonic acid – 
prostacyclin pathway (regulated by cyclooxygenase  enzyme and prostacyclin synthase) (1, 
10, 27).  
1.1.3.   Pathophysiological mechanisms and risk factors of PPHN  
 
PPHN is a clinical syndrome characterised by severe respiratory failure and hypoxemia due 
to failure of pulmonary circulation adaptation after birth. Usually PPHN is secondary to an 
underlying parenchymal lung disease (MAS, RDS, and pneumonia/sepsis) or a primary 
disease without an identifiable cause (1, 10, 13). The potential mechanisms involved in the 
pathogenesis of PPHN include: abnormal vasoconstriction of pulmonary vasculature 
following parenchymal lung diseases, abnormal pulmonary vasoreactivity and structural 
remodelling, and hypoplasia or underdevelopment of pulmonary vessels due to congenital 
diaphragmatic hernia or lung hypoplasia (1, 13, 27). 
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MAS is the far most common cause of secondary PPHN followed by pneumonia and RDS 
(11, 25). Meconium aspiration  may occur in utero or in the perinatal period and results in 
airway obstruction which causes ventilation perfusion mismatch, surfactant dysfunction, and 
release of inflammatory mediators such as interleukins (IL-1β, IL-8), tumour necrosis factor 
alpha (TNF-α), and platelet activating factor(PAF) (25). The resulting hypoxia stimulates the 
release of vasoconstrictors (ET-1, TXA2 and PGE2) with consequent maladaption of 
pulmonary circulation and extra pulmonary right –to- left shunting blood (1, 13, 27).  
Abnormal pulmonary vasoreactivity or vascular remodelling may results from excessive 
intra-uterine  pulmonary artery pressure (PAP), chronic hypoxia or from exposure to drugs 
such as  non-steroidal anti-inflammatory drugs (NSAID) (10, 14, 28), and selective serotonin 
reuptake inhibitors (SSRI) especially fluoxetine during late pregnancy (29-32). The exposure 
to NSAID increases the risk of PPHN by 6-fold by inhibiting PGI2 and TXA2 synthesis, 
resulting in premature closure of the ductus arteriosus. The exposure to SSRI after 20 weeks 
gestation results in increased levels of foetal serotonin, a potent vasoconstrictor, which 
induces vascular remodelling or proliferation  of vascular smooth muscle (33).  
Other factors which are reported to increase the risk of PPHN include perinatal asphyxia, 
being large for gestational  age( LGA), maternal tobacco smoke exposure (34), high maternal 
BMI, diabetes mellitus, pregnancy induced-hypertension and preeclampsia (35, 36), Black or 
Asian race, caesarean section and maternal asthma (36). 
1.1.4. Clinical presentation and diagnosis 
 
PPHN is usually a disease of term and post-term newborn although premature babies can also 
be affected (1). PPHN is suspected in term or near-term infants unstable shortly after birth, 
with evidence of significant differential oxygen saturation (difference of ≥ 10% between pre- 
and post-ductal saturation) or difference in arterial oxygen tension (PaO2) of  ≥ 20 mm Hg  
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associated with  severe hypoxemia that does  not improve when the infant is put on  100% 
supplemental oxygen (hyperoxia test) and which is not explained by the chest x-ray findings 
(1, 37). However PPHN is not excluded by the absence of differential saturation because the  
differential saturation  does not happen  when the right –to- left-shunting of blood occurs 
through the foramen ovale (1). Thus echocardiography is the gold standard diagnostic test for 
PPHN since it demonstrates the level and direction of shunting, measures the PAP and 
excludes congenital cardiac defect (1, 37).  
1.1.5. Treatment of PPHN 
 
The treatment goal of PPHN consists of decreasing pulmonary artery pressure and increasing 
systemic pressures to overcome the extra pulmonary right - to- left shunt and hence improve 
pulmonary blood flow and tissue oxygenation (37). The strategies that are used to achieve 
optimal oxygenation, pulmonary vascular relaxation, and to maintain adequate cardiac output 
include general supportive measures for sick infants, mechanical ventilation, surfactant 
replacement, pulmonary vasodilators and hemodynamic support by volume expansion and/or 
inotropes (dopamine, dobutamine, and adrenaline). ECMO is the last resort treatment for 
those who fail to respond to these therapies (11). General supportive measures of PPHN 
treatment include correcting the metabolic disturbances as they arise, nursing in a quiet 
environment, ensuring adequate sedation and minimal handling as these infants are sensitive 
to all kinds of stimulation.  
1.1.5.1. Mechanical ventilation 
 
Mechanical ventilation improves ventilation- perfusion (V/Q) mismatch by providing 
alveolar recruitment and adequate lung expansion. However people have moved away from 
hyperventilation approach due to lung injury and neurological complications (10). HFOV is 
the preferable mode of ventilation because it helps to improve oxygenation without or with 
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minimal lung injury compared to conventional ventilation although neither is more effective 
in preventing ECMO (38) . HFOV in combination with iNO and surfactant replacement have 
shown to reduce the need for ECMO (39-41).  
1.1.5.2. Pulmonary Vasodilators  
 
Selective pulmonary vasodilators such as iNO, phosphodiesterase inhibitors (sildenafil and 
milrinone) and magnesium sulphate play an essential role in treatment of PPHN. 
i) Inhaled nitric oxide  
 
The iNO is a fast, potent selective pulmonary vasodilator and constitutes the standard therapy 
of PPHN. The iNO is indicated in term or near-term infants (≥34 weeks of gestation). Before 
starting this treatment  the diagnosis of PPHN must be confirmed with echocardiogram and a 
right-to- left shunt ductal- dependent congenital heart defect must be excluded (14, 18).  
Although iNO reduces the need for ECMO, studies have shown that 40% of infants with 
PPHN do not respond to iNO and it does not reduce mortality or length of hospitalisation (18, 
42, 43).The iNO has dose- dependent adverse effects such as methemoglobinaemia, 
pulmonary oedema, platelets dysfunction and production of toxic metabolites. Thus, close 
monitoring of methemoglobinaemia and metabolites (NO and NO2 ) is required when using 
iNO (10). 
ii) Phosphodiesterase inhibitors  
 
Phosphodiesterase inhibitors such as Sildenafil and milrinone, used  alone or in combination 
with iNO, have shown to improve oxygenation in infants with PPHN (44).   
Sildenafil is a phosphodiesterase inhibitor type 5 (PDE5) with selective pulmonary 
vasodilator activity: it improves oxygenation by increasing cGMP levels. Oral Sildenafil has 
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been shown to be a safe and cost- effective treatment of PPHN (18, 19), largely used as an 
alternative treatment to iNO in  resource-limited settings (45, 46). A potential adverse effect 
of Sildenafil is hypotension following  systemic administration (10, 18) but is rare after oral 
administration. 
Milrinone is a phosphodiesterase inhibitor type 3 (PDE3) with an inotropic and vasodilator 
activity which increases cyclic adenosine monophosphate (cAMP) levels. A study by 
McNamara et al.(47) has shown that milrinone, when intravenously administered, improves 
oxygenation in patients with PPHN unresponsive to iNO.  
iii) Magnesium sulphate  
 
Magnesium sulphate is a calcium channel blocker with a non-selective vasodilator activity. It 
has been shown that magnesium sulphate improves oxygenation in infants with severe 
PPHN(48, 49),  and is a safe and cost-effective alternative treatment, especially in  resource- 
limited settings where iNO is not available (16, 17, 50). However randomized controlled 
trials are needed to evaluate its efficacy and safety in PPHN treatment (51). 
1.1.5.3. Extracorporeal membrane oxygenation (ECMO) 
 
ECMO refers to a cardiopulmonary bypass circuit which is used to perform gas exchange by 
using a machine in patients with severe cardiorespiratory failure. The temporary diversion of 
blood circulation by cannulation of great vessels (usually jugular vein and carotid artery in 
neonates) permits  the lungs’ rest and recovery from the injury (52, 53). The overall survival 
rate of infants treated with ECMO was estimated at 85% (range 98% in  MAS to 55% in 
diaphragmatic hernia) in a review  study by Bartlett (“Extracorporeal life support : history 
and new directions, 2005”) (52). ECMO is used as a rescue therapy for infants with 
respiratory failure and who are unresponsive to other therapies (20, 21). Its introduction  has 
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remarkably improved  the survival rate of infants suffering from PPHN and it constitutes  the 
standard therapy of PPHN in well-equipped centres (22, 23). However the use of ECMO has 
declined since the introduction of new therapies such as HFOV, surfactant and iNO. ECMO 
therapy is not readily available in developing countries due to financial and  staff  constraints 
as it is very expensive and labour  intensive (23).  
1.1.5.4. New therapies  
 
PPHN mortality rate remains high despite the current progress in mechanical ventilation and 
existing pulmonary vasodilators, especially in centres that lack ECMO (4). Thus new 
therapies target is to prevent smooth muscle cell proliferation and remodelling or stimulate 
endogenous NO production(11, 13). The new therapies which are undergoing investigation  
include antioxidants such as recombinant human superoxide dismutase, antenatal steroids 
(betamethasone) (11, 13), endothelial progenitor cells, Rho kinase inhibitors and vasoactive  
intestinal peptide (13).  
1.1.5.5.  Prevention and management of MAS  
 
MAS has significantly declined in developed countries due to improved antenatal and 
intrapartum obstetric care and neonatal care; while its incidence is still very high in 
developing countries and it is associated with high morbidity and mortality (54). In the past 
several practices including amnioinfusion, intrapartum oral and nasopharyngeal suction, 
gastric lavage, and  intubation and suction of all infants born through meconium stained 
amniotic fluid (MSAF)  had been recommended (during different periods of time) in order to 
prevent MAS. However those practices have been abandoned by obstetricians and 
neonatologists as it was shown that they did not prevent MAS in randomised clinical trials 
(54, 55). The current recommendations from the American National Resuscitation Program 
(NRP), the American Academy of Paediatrics (AAP) and the American College of Obstetrics 
10 
 
and Gynaecology (ACOG) (54), which  have been adopted by South  African neonatal  
resuscitation program . With  regard  to  MAS prevention and management of infants born 
through MSAF, these recommendations include: i) close intrapartum monitoring of foetal 
heart rate and the presence of a staff with skills in neonatal resuscitation at delivery of at-risk 
pregnancy, ii) intubation and endotracheal suction of depressed infants born through MSAF, 
iii) early initiation of assisted ventilation and surfactant replacement therapy for respiratory 
depressed and hypoxic infants (54, 55). 
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2. PATIENTS AND METHODS 
 
2.1.   Patients and methods 
 
The present study is a retrospective descriptive study of newborn infants with a discharge 
diagnosis of persistent pulmonary hypertension of the newborn (PPHN). The infants included 
both inborn and out born neonates admitted at CMJAH neonatal unit from January 2006 to 
December 2013. 
The data for this study was retrieved from a computerised neonatal database of CMJAH 
neonatal unit. Neonatal data is collected and managed using the REDCap (Research 
Electronic Data Capture) software hosted by the University of the Witwatersrand. Data is 
collected on discharge for each infant for the purpose of clinical audit. Infants with a 
discharge diagnosis of PPHN were identified by reviewing the computer database. Maternal 
and infant data were retrieved from the computer data base and completed by a review of 
medical records if necessary.  Maternal data consisted of age, parity, gravidity, and disease 
during pregnancy, NSAID use and mode of delivery while the infant data consisted of 
gestational age, birth weight, gender, and place of birth, Apgar score, ventilation mode and 
duration, drug therapy in ICU, echocardiograph findings, hospital stay and outcome on 
discharge. Intensive care unit (ICU) charts were not available so ventilation parameters were 
not available and we were unable to calculate the oxygenation index in order to determine the 
severity of respiratory failure. 
The diagnosis of PPHN was made on clinical presentation by attending physician when a 
patient was unstable immediately after birth; he/she had differential oxygen saturation 
(difference between pre-ductal and post-ductal) ≥ 10 % or difference in arterial PO2 ≥ 20 
mmHg, hypoxemia disproportionate to the chest x-ray changes and was unresponsive to 
hyperoxia test. Due to a shortage of paediatric cardiologists at CMJAH, echocardiography to 
12 
 
confirm PPHN was usually performed at a later stage; and not all patients included in the 
study had echocardiography. 
Preterm and term infants, inborn or out born, who fulfilled the criteria were included in this 
study. Infants with congenital diaphragmatic hernia were also included in the study while 
those who had a cyanotic congenital heart defect on echocardiography were excluded. We 
also excluded the patients whose data were not retrievable either from either the computer 
database or medical records. 
Patients were managed by the attending physician according to the unit protocols. All infants 
who are clinically suspected to suffer from PPHN were usually ventilated mainly with 
conventional mechanical ventilation (CMV) and those who failed CMV were changed to 
HFOV. All infants on assisted ventilation were sedated with venous boluses of 
morphine/fentanyl with or without a benzodiazepine (midazolam) and most patients were not 
paralyzed. Sildenafil and magnesium sulphate were the only pulmonary vasodilators used. 
The unit did not offer iNO or ECMO treatment during the study period. However CMJAH 
has the capacity to offer iNO and ECMO treatment to some patients with severe respiratory 
failure in the cardiothoracic surgery unit. 
The adjuvant therapy for PPHN included exogenous surfactant for RDS or severe MAS and 
hemodynamic support by inotropes (dopamine, dobutamine and adrenaline) when indicated. 
Sodium bicarbonate infusion was frequently used in treatment of severe metabolic acidosis to 
keep pH ≥7.25 if the latter is not corrected by ventilation and improved perfusion. However 
hyperventilation was not used in our unit. The general measures of treatment that were used 
include an attitude of ‘minimal’ handling and correction of metabolic disturbances when 
indicated. 
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2.2.  Statistics  
 
The data was described using standard statistical methods. Categorical variables were 
described using frequency and percentages, while continuous variables were described using 
mean and standard deviation or median and range, depending on data distribution. The 
univariate analysis was done using Pearson Chi square test and Fisher exact test for 
categorical variables, while Student’s t- test or Mann -Whitney  tests were used for 
continuous variables where appropriate in order to compare maternal and infant characteristic 
between survivors and non-survivors. Statistical significance was accepted at p-value <0.05.  
2.3.  Ethics  
 
Permission to conduct the study was obtained from the University of Witwatersrand human 
research ethics committee and from the CMJAH authority (clearance certificate number 
M130650).  
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3.  RESULTS  
 
During the 8-year period there were estimated 219,514 live births from CMJAH and its 
referring, surrounding health care clinics. Eighty- one patients were identified with a 
discharge diagnosis of PPHN. Of the 81 patients, 72 were included in the study and 9 were 
excluded. Six patients were excluded because they had major congenital heart defect other 
than PDA or PFO on echocardiography; two were excluded because the relevant data was 
irretrievable from either the computer database or medical records and 1 was excluded 
because the discharge diagnosis of PPHN had been allocated to him erroneously. The 
estimated incidence of PPHN at the CMJAH neonatal unit was 0.33 per 1000 live births. 
The patients’ mean birth weight was 2.94 kg (SD 0. 69) 95% CI (2.77, 3.10), and the mean 
gestational age was 38.2 weeks (SD 3.3) 95% CI (37.4, 38.9). The maternal mean age at 
delivery was 26.2 years (SD 5.8) 95% CI (24.5, 27.9).  
Echocardiography to confirm the diagnosis of PPHN by demonstration of right- to- left shunt 
was only performed in 27 patients (37.5%) of whom 10 patients (37%) had either a PDA and 
PFO or a PDA only with a right -to- left shunt. 
 Maternal diseases during pregnancy and demographics are shown in Tables 1 and 2. 
Table 1. Maternal disease during pregnancy 
Maternal disease  Frequency (%)  (  n=72) 
PIH  
Diabetes  
Tuberculosis  
None  
Asthma  
NSAID 
5 (6.9) 
1(1.4) 
1(1.4) 
59 (81.9) 
0 
0 
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Most of the mothers 59(81.9%) did not have chronic or pregnancy - related disease 
predisposing their infants to PPHN. However 5 mothers (6.9%) had pregnancy - induced 
hypertension (PIH). None of the mothers reported non-steroid anti-inflammatory drug 
(NSAID) use during pregnancy. 
Table 2. Demographic characteristics of the patients 
Characteristics                                                        Frequency (%)   (n=72) 
   Female   
   Delivery mode: 
  Vaginal  
  Caesarean section  
   Inborn       
  Apgar at 5 min   < 7  
   Birth weight /GA  
     AGA      
      SGA    
      LGA       
  Gestation age groups 
      Premature ( ≤ 34) 
      Late premature ( 35-36 ) 
      Term  (≥37) 
37(51.4) 
 
38(52.8) 
31(43.1) 
44(61.1) 
                              16(22.2) 
 
58(80.6) 
9(12.5) 
4(5.6) 
 
10(13.9) 
7(9.7) 
54(75.0) 
 
The majority of infants were born at term 54(75%) and inborn 44(61.1%); almost half of the 
patients were female 37(51.4) and born by vaginal delivery 38 (52.8%). Sixteen (22%) had a  
5 minute Apgar score below 7. Different pathologies associated with PPHN are shown in 
Table 3.  
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Table 3. Patients’ underlying pathologies 
Underlying Pathology       Frequency (%)  (n=72) 
 
 Meconium aspiration syndrome (MAS) 
Congenital pneumonia  
Respiratory distress syndrome (RDS) 
Asphyxia* 
MAS/Asphyxia 
Idiopathic PPHN 
Sepsis  
TTN 
Hypoplastic lung  
Congenital diaphragmatic hernia(CDH) 
Pulmonary haemorrhage  
Vein of Galen malformation 
43 (59.7) 
9 (12.5) 
6 (8.3) 
2(2.8) 
3(4.2) 
2(2.8) 
1(1.4) 
1 (1.4) 
1 (1.4) 
2(2.8) 
1 (1.4) 
                            1(1.4) 
 
*Asphyxia was defined by low Apgar of ≤ 5 at 10 min, pH ≤7.0 and base excess of ≤ -16, 
neurological fall out and evidence of multi-organ dysfunction. 
MAS was reported in 43 patients (59.7%) and it was the most common underlying pathology 
seen, followed by congenital pneumonia and respiratory distress syndrome, accounting for 
9(12.5%) and 6(8.3%) respectively. 
Although CMJAH is a surgical referral centre, especially for level 2 hospitals in 
Johannesburg, only 7 patients were admitted with congenital diaphragmatic hernia during our 
study period: only 2 of these patients had PPHN and both of them did not survive.  
The management and outcome of patients with PPHN are shown in Table 4. 
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Table 4. Drug therapy, mechanical ventilation and outcome 
Therapy    Frequency (%)   (n=72) 
Mechanical ventilation  
Yes  
No 
Mode of ventilation (n=66) 
CMV 
HFOV 
Surfactant use 
Yes  
No 
Bicarbonate infusion  
Yes  
No  
Inotropic support  
Yes  
 No  
Vasodilators use  
     Magnesium sulphate  
     Sildenafil  
     Inhaled nitric oxide 
     Nil vasodilator given  
Number of deaths 
 
67 (93.1) 
5  (6.9) 
 
67(100) 
13(18.1) 
 
14(19.4) 
57(79.2) 
 
16(22.2) 
56(77.8) 
 
38(52.8) 
34(47.2) 
 
                       12(16.7) 
9(12.5) 
0 
50(69.4) 
25(34.7) 
 
 
Almost all the patients required mechanical ventilation 67(93.1%), 13 patients (18.1%) failed 
CMV and required HFOV. The median duration of mechanical ventilation was 4 days (range: 
0 - 31). A slight majority of patients 38(52.8%) needed inotropic support while few patients 
16 (22.2%) and 14(19.4%) were given sodium bicarbonate infusion or surfactant replacement 
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therapy respectively. Of the 43 patients who had MAS, only 7(16.3%) were treated by 
exogenous surfactant.  Magnesium sulphate and Sildenafil were used in 12(16.7%) and 
9(12.5%) patients respectively. Although the iNO is a standard therapy of PPHN, this was not 
available in the unit during the study period. Surprisingly 5 patients (6.9%) did not require 
mechanical ventilation. 
The mortality rate was 34.7% (25 patients) and the majority (62.5%) died in the first 24 hours 
of admission. The median duration of hospital stay was 8 days (range: 0- 42). 
The comparison between survivors and non-survivors is shown in Tables 5, 6 and 7. 
Table 5. Comparison between Survivors and non survivors 
Characteristics       
(Mean±SD or Median and range  ) 
Died                   Discharged               p-value  
 
Birth weight (kg) 
 
Agars score at 5min  
 
Gestation age(weeks) 
 
Duration of ventilation (days) 
 
Duration of hospital stay(days) 
 
 
2.82  ±  0.77              2.99   ± 0.64           0.30 
 
7.24 ±  1.37               7.26  ±1.46             0.95                  
 
37.71 ± 3.88             38.43± 2.98            0.39 
 
1(0-26)                       6 (.0-31)               0.000* 
 
1(0-36)                       7(1-32)                 0 .000* 
 
 
*median (range), Mann-Whitney test  
There was no difference between survivors and non- survivors  in regard to birth weight, 
Apgar score at 5 minutes  and  gestation age (p > 0.05) while  the duration of ventilation and 
hospital stay was longer for  the survivors than non- survivors (p= 0.000) (Table 5).  
 
 
 
19 
 
Table 6.Comparison of demographic characteristics and treatment modalities between             
Survivors and non- survivors   
Patients characteristics /treatment Died (n=24)               Discharged (n=47)            p-value 
(%)                                (%) 
Mode of delivery (n=68)  
Vaginal 
Male  
Apgar 5- min <7 (n= 63) 
Inborn  
Gestational age  (n=70) 
Preterm (<37weks) 
Term (≥ 37weeks) 
Birth weight/GA (n=70) 
AGA 
LGA or SGA 
Mechanical Ventilation 
CMV/HFOV 
HFOV 
Inotrope support 
Vasodilators use(n=71) 
Type of vasodilator (n=20) 
Magnesium sulphate 
Sildenafil 
Bicarbonate infusion 
Surfactant use 
                                                                          0.23 
15  (65.2)                  23(50) 
15 ( 60)                     27 (57.4)                         0.15 
8(38.1)                        8(19)                             0.10 
12(48)                       32(68.1)                          0.09 
                                                                         0.88 
6(25)                       11(23.4) 
18(75)                     36(76.6) 
                                                                         0.75 
19 (79.2)                 39(83) 
5(20.8)                      8(17) 
25(100)                    42(89.4)                           0.15 
18(72)                      36(85.7)                           0.20 
7 (28)                         6(12.8)                           0.12 
18(72)                      20(42.6)                           0.01 
10(41.7)                   11(23.4)                           0.11 
                                                                         0.38 
7 (66.7)                      5(45.5) 
3(30)                          6(54.5) 
8(32)                          9(19.1)                           0.22 
6(25)                          8(17)                              0.53 
                  
The demographic characteristics or treatment modalities were similar between survivors and 
non-survivors except for the need for inotropic support, where the use of inotropes was 
associated with poor outcome (p = 0.01) (Table 6). 
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Table 7. Comparison of survivor and non-survivors by underlying pathologies 
Underlying pathology Died                      Discharged       p-value 
     (%)                              (%) 
MAS (n=43) 
Congenital pneumonia(n=9) 
RDS (n=6) 
MAS and Asphyxia (n=3) 
Asphyxia (n=2) 
Idiopathic PPHN (n=2) 
Sepsis (n=1) 
TTN   (n=1) 
Hypoplastic lung (n=1) 
CDH (n=2) 
Pulmonary haemorrhage (n=1) 
Vein of Galen malformation (n=1) 
Total  (N=72) 
12(27.9)                      31(72.1)              
2(22.2)                         7(77.8) 
3(50)                            3(50) 
2(66.7)                         1(33.3) 
 -                                   2(100) 
1(50)                             1(50) 
1(100)                           - 
 -                                   1(100) 
1(100)                            -       
2(100)                            -        
 -                                   1(100) 
1(100)                                     - 
25(34.7)                      47 (65.3)            0.17 
 
There were no statistically significant difference between survivors and non-survivors in 
regard to the underlying pathologies (p=0.17) though MAS was the most frequent cause of 
PPHN. 
MAS was the most frequent associated disease in this study and the characteristics of patients 
with MAS are shown in Table 8. 
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Table 8. Characteristics of patients with MA 
Characteristics     (n=43)         
                            Frequency (% )             p-value                        
Gender :                                        
   Female                                   
Gestational age  
   Preterm (<37) 
  Term  (≥ 37)  
Mode of delivery  
   Vaginal  
   Caesarean section  
Place of birth  
    Inborn  
    Out born 
Surfactant therapy 
   Yes  
    No  
Mechanical ventilation  
   Yes                                                                               
    No  
Outcome                                                  
    Died   
    Discharged    
                                                                                         
26  ( 60.5) 
 
8  (18.6) 
35 (81.4) 
 
21(51.2) 
20(48.8) 
 
26(60.5) 
17(39.5) 
 
7( 16.7) 
35(83.3 ) 
 
40(93) 
3( 7) 
                                                               0.20 
12(27.9 ) 
31( 72.1) 
 
Majority of infants with MAS 35(81.4%) were born after 37 weeks of gestation and almost 
all of them required mechanical ventilation 40(93%) though few patients 7(16.7%) were 
treated with surfactant. MAS was more frequent in female and inborn infants 26(60.5%) each 
and slight majority 21(51.2%) were born by vaginal delivery. The mortality rate in patients 
with MAS was slightly lower (27.9%) than the overall mortality (34.7%). However there was 
no statistically significant difference between patients with MAS mortality and those without 
MAS (p = 0.20). 
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4.  DISCUSSION  
 
Meconium aspiration syndrome was the leading cause of PPHN in this study, accounting for 
43 cases (59.7%). Approximately 3 to 4 % of infants born through meconium stained 
amniotic fluid liquor (MSAF) develop MAS.  MSAF complicates 7 to 22% of term deliveries 
and up to 52% of postdate deliveries ( ≥42 weeks gestation) (56). The incidence of MAS has 
recently declined due to improved obstetric practices including the reduction of postdate 
deliveries (>41 weeks gestation),  good  intrapartum monitoring of foetal heart rate as well as 
resuscitation of depressed neonates born through MSAF (57).  
Both international and South African neonatal resuscitation programs recommend that all 
infants born through MSAF and who are depressed must be intubated and suctioned in order 
to clear the meconium substance from the trachea and oropharynx to prevent meconium 
aspiration (55, 58). 
 Remarkable progress has been made in pathophysiology understanding and treatment of 
PPHN (10, 11, 13, 14). However PPHN remains a treatment challenge for neonatologists 
especially in developing countries and its mortality rate remains high in resource-limited 
settings (5-9, 59, 60). 
Of the 72 patients included in our study 61.1% were inborn, almost half of the patients were 
female and born by vaginal delivery (51.4% and 52.8% respectively); 80.6% had appropriate 
birth weight for gestational age.  These results differ from those reported in previous studies 
which reported that PPHN was more associated with male sex, LGA and caesarean section 
delivery (5, 6, 9, 28, 36, 59, 60). The majority of the patients included in this study (75%) 
were born after 37 weeks, the mean gestation age being 38.2 weeks (SD 3.3) and the mean 
birth weight was 2.94 kg (SD 0.69). These results were similar to those reported in the 
literature and were consistent with the evidence that PPHN mainly affects term and post-term 
infants (9, 11, 60). The maternal mean age at delivery was 26.32 years (SD 5.8). Only 5 
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patients (6.9%) had PIH as a known risk factor although it could be underestimated since 
maternal history was not well documented in infant’s medical records. Similar maternal age 
at delivery was reported in previous studies by Roofthooft in the Netherlands (59), and 
Hernandez in USA (36). The most frequent underlying disease leading to PPHN was MAS 
(59.7%) followed by pneumonia and RDS (accounting for 12.5% and 8.3% of the patients 
respectively). In the literature, MAS has been unanimously reported by many authors as the 
most frequent lung parenchyma disease resulting in PPHN, followed by idiopathic PPHN and 
pneumonia or RDS (1, 10, 11, 13, 61) (see Table 9). Our results were similar to those 
reported in previous studies (2, 6, 7) except that idiopathic PPHN accounted for only 2.8% in 
our study.  
 
Table 9.  Summary of PPHN causes in different studies 
Series  MAS        Pneumonia     RDS          Asphyxia              Idiopathic  
      (%)           ( %)                    ( % )               (  % )               ( %) 
Konduri,2009  
Razzaq et al.,2013  
Abdel et al.,2013  
Smith et al.,1993 
Hernandez et al.,2007  
Rocha et al.,2012 
Our study  
       42            13                      17                   -                         27 
       35.4         29.1                  13.9                40.5                     - 
       50            31.25                18.75            43.75                    12.4            
       34.3           -                          -                   11.4                 -  
       47.5          30.8                  50.4                    -                    12.8        
       24.3          3.8                       -                   30.7                  - 
       59.7          13.9                    8.3                   2.8                  2.8 
 
Of the 72 patients enrolled in our study 93.1% were mechanically ventilated preferentially by 
CMV; 18.1% of them failed conventional mechanical ventilation and were switched to 
HFOV while 5 patients (6.9%) did not require assisted ventilation. Fourteen patients (19.7%) 
24 
 
were treated with exogenous surfactant. Similar results were reported in a previous study by 
Rocha et al. (9) in which 30.7% patients were treated with exogenous  surfactant.  These 
results were consistent with the existent knowledge in the literature since it has been 
stipulated that assisted ventilation constitutes the mainstay of PPHN treatment (1, 13-15, 61). 
The high proportion of patients treated by mechanical ventilation and surfactant in our study, 
could explain the severity of their disease though we were unable to calculate the patients’ 
oxygenation index. The oxygenation index is usually used to measure the severity of 
respiratory failure (1, 25) .  None of the patients was treated with iNO or ECMO since our 
unit did not offer these types treatment.  
Magnesium sulphate and Sildenafil were frequently used in this study (16.7% and 12.5% of 
patients respectively) for pulmonary vasodilatation. Similar findings were reported in 
previous studies (6, 48, 62) and it has been shown that magnesium sulphate and Sildenafil are 
valuable, safe and cost-effective alternative vasodilators for the treatment of PPHN in 
resource- limited settings when iNO is not available (50, 63) . 
Although alkali infusion and hyperventilation have nowadays lost the favour of 
neonatologists in the treatment of PPHN due to associated neurological complications and 
development of chronic lung disease (1, 2), sodium bicarbonate infusion was used in 22.2% 
of our patients. Similar findings were reported by Abdel et al. in Egypt (6),where sodium  
bicarbonate infusion was given to 25% of patients. An alkali infusion overall  rate of  75%   
was reported by Walsh-Sukys et al. (2) in a multicentre study in USA, where 92% of patients 
received sodium bicarbonate infusion. 
Of note, there were no comments about potential complications such as neurosensory 
deafness and chronic lung disease at discharge found in patients’ medical records. Long term 
follow up data was not available. 
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Adequate cardiac output and improved perfusion or oxygenation can be achieved either by 
volume expansion or inotropic support or both (10, 11, 14, 37). However inotropes should be 
used cautiously since they can also increase the PAP and worsen the right -to- left shunt(10). 
A slight majority of our patients (52.8%) required inotropic support. The results were 
comparable to those reported Walsh-Sukys et al. (2)  in a multicentre study in which inotropic 
support overall  was 84% (range 46-100%) with variation between centres.   
Despite remarkable advances in understanding of physiopathology and managing PPHN, its 
mortality rate is still high in limited – resource settings or developing countries (4).  Of the 72 
patients enrolled in this study 25 (34.7%) did not survive. Similar high mortality rates directly 
or indirectly related to PPHN were reported in previous studies across the world:  48% at 
Chris Hani Baragwanath Hospital (8) and 31% at Tygerberg Children’s Hospital (7) in South 
Africa, 25% at  Al-Minya University Hospital  in  Egypt (6), 26.6% at Children’s Hospital 
,Multan in Pakistan (5), 32% at Hospital de Sᾶo Joᾶo EPE in  Portugal (9) and 27.6% at 
Chang Gung Children’s Hospital  in Taiwan (60) .  High PPHN mortality, in limited-resource 
settings, may be attributed to lack of new therapies such as HFOV, iNO and ECMO, which is 
the rescue therapy for patients with severe PPHN unresponsive to other treatment modalities. 
Of note, 40% of neonates with PPHN do not respond to the combination   therapy of HFOV 
and iNO and require ECMO as a last resort treatment (3, 10, 13).  
A great concern in this study is that of 25 patients 62.5% died in the first 24 hours of 
admission. None of the patients was treated with iNO or ECMO; it was not possible to 
measure the severity of disease /respiratory failure since there was no ventilation parameters 
available to calculate oxygenation index either before or after the treatment initiation. 
On univariate analysis, the patients’ characteristics were similar for survivors and non-
survivors except the need of inotropic support which was associated with poor outcome 
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 (p = 0.01) and the duration of mechanical ventilation or hospital stay which was longer for 
survivors than non-survivors (p = .000) (Tables 6 & 7). Theses differences are to be expected 
as deaths occurred early. 
5.  CONCLUSION AND RECOMMENDATIONS  
5.1. Conclusion  
 
In this study PPHN was more frequent in female infants and associated with vaginal delivery. 
MAS was the most frequent underlying disease leading to PPHN. Patients’ characteristics 
were similar between survivors and non survivors. Magnesium sulphate and Sildenafil were 
the only pulmonary vasodilators used .There was a high mortality rate 25(34.7%) and neither 
treatment strategy influenced the outcome, though the need for inotropic support was 
associated with poor outcome.  
The low incidence of PPHN in this study could be explained by the improved management of 
infants with MAS in this unit, following the international recommendations (54, 55) 
mentioned earlier in the text, regarding the “delivery room management” of infants born 
through MSAF and neonatal resuscitation. 
Due to its retrospective design, this study had some limitations: a) there were some missing 
data regarding patients’ characteristics; b) it was not possible to calculate the IO since there 
were no ICU charts available, therefore it was impossible to measure the severity of 
respiratory failure; c) only a few patients in this study had an echocardiography and  therefore 
there was a possibility of underestimating PPHN by relying on clinical diagnosis as the 
incidence in our setting is lower than in other reports.  
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5.2. Recommendations  
 
ECMO therapy is very expensive and labour intensive, thus currently inaccessible in 
resource-limited settings. The reduction of MAS incidence by improving antenatal and 
intrapartum obstetric care, reduction of postdate deliveries (> 41weeks of gestation), good 
monitoring of at-risk pregnancies , adequate management of infants born through MSAF; and 
adequate neonatal resuscitation, surfactant replacement therapy and early initiation of  
assisted ventilation for depressed neonates with MAS  could be a cost-effective measures in 
mitigating PPHN.  
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